First in Human, Dose Escalation Study of AN4005
First in Human, Dose Escalation Study of AN4005
Recruiting · NCT04999384 · Registry updated 2025-11-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First in Human, Dose Escalation Study of AN4005 | Advanced Lymphoma; Advanced Solid Tumor | Recruiting | Phase 1 | 2025-11-18 | NCT04999384 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Adlai Nortye Biopharma Co., Ltd. | 4 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | 208 |
| Hackensack University Medical Center | Hackensack | United States | 308 |
| Harbin Medical University Cancer Hospital | Harbin | China | 102 |
| Montefiore Einstein Cancer Center | The Bronx | United States | 7 |
| NEXT Virginia | Fairfax | United States | 83 |
| Prisma Health Institute for Translational Oncology Research | Greenville | United States | 1 |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan | China | 12 |